


PHARMACEUTICAL 2022

Sio Gene Therapies Inc. Rank 137 of 475







Sio Gene Therapies Inc. Rank 137 of 475

The relative strengths and weaknesses of Sio Gene Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sio Gene Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 130% points. The greatest weakness of Sio Gene Therapies Inc. is the variable Revenues, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 6.6%, being 283% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	132,333
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,848
Liabilities, Non-Current	932
Other Assets	2,336
Other Compr. Net Income	390
Other Expenses	587
Other Liabilities	0
Other Net Income	10,359
Property and Equipment	478
Research and Development	24,903
Revenues	0
Selling, General and Administrative Expense	17,294

Output Variable	Value in 1000 USD
Assets	135,147
Liabilities	11,780
Expenses	42,784
Stockholders Equity	123,367
Net Income	-32,425
Comprehensive Net Income	-32,230
Economic Capital Ratio	6.6%

